CMBA
ARCT icon

C.M. Bidwell & Associates’s Arcturus Therapeutics ARCT Stock Holding History

C.M. Bidwell & Associates’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-131
Closed -$5K – 534
2021
Q4 		$5K Hold
131
– – ﹤0.01% 427
2021
Q3 		$6K Hold
131
– – ﹤0.01% 422
2021
Q2 		$4K Buy
+131
New +$4.43K ﹤0.01% 485

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

C.M. Bidwell & Associates's ARCT Position: Q1 2022 in Review

C.M. Bidwell & Associates sold out of Arcturus Therapeutics (ARCT) in Q1 2022, closing a stake of 131 shares — an estimated $5K sold.

C.M. Bidwell & Associates first reported a position in ARCT in Q2 2021 and held it in 3 quarters. The position peaked at $6K in Q3 2021. 130 funds tracked by Wall St. Rank hold ARCT as of Q1 2022.

  • C.M. Bidwell & Associates reported no remaining Arcturus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 131 Arcturus Therapeutics shares in Q1 2022, an estimated $5K.
  • C.M. Bidwell & Associates first reported a position in Arcturus Therapeutics in Q2 2021 and held it in 3 quarters.
  • C.M. Bidwell & Associates's Arcturus Therapeutics position peaked at $6K in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2022, filed 29 Apr 2022.